Host Immunity to Fungi . Neutrophil Biology in Infection . T-Cell Therapies Implant Infections with Staphylococcus Aureus and Epidermidis
Host pathogen interaction in infectious diseases
The infection biology research group explores host- and pathogen-specific aspects of infectious diseases in a strong translational setting. Our main focus is to understand the interaction of innate and adaptive immune responses in the context of bacterial, fungal and viral infections with the aim at elucidating key mechanisms of immune protection, thus fostering personalized treatment – with the overarching goal to improve clinical outcome.
Host response to fungal infections
Invasive fungal infections are devastating in immune compromised patients and associated with high mortality rates despite treatment. Risk assessment and diagnosis remain a major challenge leading to administration of broad-spectrum antifungal prophylaxis and over-treatment, which in turn is associated with high costs,drug interactions and, most importantly, limited clinical efficacy with emergence of resistant strains. Hence, reliable tools to identify patients at risk and tailored treatment strategies to improve patient outcome are urgently needed.
We recently found that functional neutrophil, NK-cell and Aspergillus fumigatusspecificTh1 immunity is associated with a better outcome in patients after allogeneic hematopoietic stem cell transplantation (HSCT) with invasive aspergillosis (Fig. 1A).
To get a broader knowledge about immunological factors increasing the susceptibility to fungal infections in other patient populations, we further studied risk factors for development of Candida esophagitis in HIV-infected patients. We found that HIV-1-infected patients with Candida esophagitis had an accumulation of multiple,partly Candida-specific immunological defects (Fig. 1B). In addition, longterm immune recovery was impaired even after introduction of combination antiretroviral therapy, illustrating that specific immunological gaps persist in these patients. These data clearly support the rationale for early combination antiretroviral therapy initiation to prevent irreversible immune defects.
Adoptive T-cell therapy for infectious diseases
Adoptive transfer of pathogen-specific donor-derived T cells is to date the most promising and feasible immunotherapeutic strategy in transplant recipients restoring the lacking T-cell function. Its potential as prophylactic or therapeutic treatment has been demonstrated for viral infections after transplantation. We recently initiated a clinical trial of adoptive T-cell therapy for treatment-refractory viral infections with cytomegalovirus, Epstein Barr virus and adenovirus after HSCT using the cytokine capture assay® (Miltenyi Biotec) at the University Hospital of Basel (ClinTrials ID NCTO2007356), which is so far unique in Switzerland.
The fact that higher Aspergillus fumigatus-specific Th1 responses correlate with abetter clinical outcome in HSCT recipients with invasive aspergillosis encourages the development of antifungal T-cell transfer. We recently identified immunogenic Aspergillus fumigatus antigens, which are likely protective by inducing Th1-cellresponses in healthy individuals and HSCT recipients with well-controlled invasive aspergillosis (Fig. 2A,B). We were further able to select these antigen-specific cells based on activation-dependent expression of CD137 or CD154 with aGMP-compliant protocol (Fig. 2C). Moreover, cell lines containing T cells specific for all three proteins cross-reacted to the most relevant human-pathogenic molds(Fig. 2D). These results greatly foster adoptive T-cell therapy for these problematic infections.
Staphylococcal implant infections
Bacterial infection of implanted devices is a major health care problem occurring in about 5 % of patients. These infections are mainly caused by biofilm-formingstaphylococci, which are generally tolerant to antibiotic treatment. We could recently demonstrate that silver-coating can efficiently prevent implant-associated infections and thus can be considered for clinical application (Fig. 3). Further studies are on the way investigating the host pathogen interaction in biofilm-associated infections.